Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV)

Q: What does CUSIP 004890109 represent in this 13F holders report?

CUSIP 004890109 is the security identifier for ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q4 2022?

18 institutional investors reported ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q4 2022. Use the holders table for investor-level position and value details.

CUSIP: 004890109

Q4 2022 13F Holders as of 31 Dec 2022

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 38,870,454
Total 13F shares: 14,965,637
Share change: +14,965,637
Total reported value: $170,360,092
Price per share: $11.52
Number of holders: 18
Value change: +$170,360,092
Number of buys: 18

Quarterly Holders Quick Answers

What is CUSIP 004890109?
CUSIP 004890109 identifies ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q1 2023

Recent filing periods for CUSIP 004890109:

Q4 2025 Q3 2025 Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024

Top shareholders of ACRV - Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Wellington Biomedical Innovation Master Investors (Cayman) I L.P.	3/4/5	10%+ Owner	— class O/S missing	888,130	$3,863,366	—	17 Nov 2022	3/4/5

Institutional Holders of Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) as of Q4 2022

As of 31 Dec 2022, Acrivon Therapeutics, Inc. - Common Stock, par value $0.001 per share (ACRV) was held by 18 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 14,965,637 shares. The largest 10 holders included RA CAPITAL MANAGEMENT, L.P., PERCEPTIVE ADVISORS LLC, Sands Capital Ventures, LLC, CITADEL ADVISORS LLC, MARSHALL WACE, LLP, WELLINGTON MANAGEMENT GROUP LLP, FEDERATED HERMES, INC., NEA Management Company, LLC, HealthCor Management, L.P., and BANK OF MONTREAL /CAN/. This page lists 18 institutional shareholders reporting positions in this security for the Q4 2022 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q4 2022 vs Q3 2025 Across Filers

Q3 2025 holders

Q4 2022 holders

Holder diff

-27

Investor	Q3 2025 Shares	Q4 2022 Shares	Share Diff	Share Chg %	Q3 2025 Value $	Q4 2022 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.